Saturday 17 October 2026
Export SGHT’s income statement to Excel — free account
Sight Sciences, Inc.
SGHT Healthcare Medical Devices
Sight Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $77.4 million, down 3.13% from fiscal 2024. In the quarter to June 2026, revenue grew 19.6%, EPS grew 65.2%, free cash flow grew 26.7% and total debt rose 2.40%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.28
0.52
−5.91%
Follow SGHT
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 17.00 | 5.35 | 1.04 | 3.30 | 2.03 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 42.57 | 18.40 | 15.30 | 8.45 | 9.24 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 184 | 212 | 250 | 214 | 216 | 186 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.15 | 0.23 | 0.29 | 0.38 | 0.37 | 0.42 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | 8 | 23 | 28 | 49 | 71 | 81 | 80 | 77 | ||||
| Gross margin, % | — | — | 68.95 | 71.97 | 66.68 | 82.41 | 82.67 | 85.34 | 85.50 | 86.17 | |||||
| EBT | — | — | (14) | (26) | (35) | (63) | (86) | (55) | (51) | (38) | |||||
| EBT margin, % | — | — | (189.85) | (110.76) | (125.30) | (128.22) | (120.84) | (68.39) | (64.20) | (49.66) | |||||
| Net income | — | 0 | (14) | (26) | (35) | (63) | (86) | (56) | (52) | (38) | |||||
| Depreciation | — | — | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.16 | 0.50 | 2.95 | 1.83 | 1.49 | 1.67 | 1.59 | 1.48 | ||||
| Earnings | — | — | (0.31) | (0.55) | (3.71) | (2.36) | (1.80) | (1.14) | (1.03) | (0.74) | |||||
| Cash flow | — | — | (0.31) | (0.53) | (3.44) | (1.97) | (1.59) | (0.97) | (0.45) | (0.57) | |||||
| Capex | — | — | 0.00 | 0.00 | (0.10) | (0.03) | (0.02) | (0.02) | (0.01) | 0.00 | |||||
| Free cash flow | — | — | (0.31) | (0.53) | (3.54) | (2.00) | (1.61) | (0.99) | (0.45) | (0.57) | |||||
| Book value | — | — | (0.62) | (1.17) | (9.50) | 8.68 | 3.35 | 2.47 | 1.75 | 1.23 | |||||
| Shares, m | — | — | 47 | 47 | 9 | 27 | 48 | 49 | 50 | 52 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | 8.29 | 8.29 | 8.29 | 9.59 | 8.26 | 3.06 | 2.28 | 5.35 | |||||
| P/B | — | — | 0.00 | 0.00 | 0.00 | 2.02 | 3.68 | 2.06 | 2.09 | 6.47 | |||||
| EV/Sales | — | — | 8.21 | 8.21 | 8.21 | 4.95 | 6.15 | 1.77 | 1.30 | 4.71 | |||||
| EV/FCF | — | — | (7.37) | (7.37) | (7.37) | (4.54) | (5.70) | (3.00) | (4.56) | (12.11) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (14) | (25) | (32) | (53) | (76) | (47) | (22) | (30) | ||||
| Capex | — | — | (1) | (1) | (1) | (1) | (1) | (1) | 0 | 0 | |||||
| Free cash flow | — | — | (14) | (25) | (33) | (53) | (77) | (48) | (23) | (30) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 4 | 21 | 61 | 264 | 192 | 151 | 124 | 102 | ||||
| Total debt | — | — | 34 | 78 | 32 | 33 | 34 | 34 | 39 | 40 | |||||
| Net debt | — | — | 30 | 57 | (29) | (228) | (151) | (104) | (81) | (52) | |||||
| Shareholders’ equity | — | — | (29) | (55) | (89) | 232 | 160 | 120 | 88 | 64 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (353.10) | (133.23) | (67.01) | (35.67) | (34.97) | (29.26) | (33.29) | (29.77) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (701.56) | (556.90) | (223.54) | (484.25) | (188.86) | |||||
| ROE | — | — | 34.17 | 61.85 | 48.34 | (87.90) | (43.98) | (39.64) | (49.59) | (50.74) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Sight Sciences, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TCMD Tactile Systems Technology, Inc. | $527.6M | 20.5× | 22.7× | +8.61% (above 0%: growing) | +142.86% (above 0%: growing) | −86.53% (below 0%: shrinking) | 76.25% | 7.97% | Compare |
| SSII SS Innovations International, Inc. | $517.2M | — (loss-making) | — (loss-making) | +39.39% (above 0%: growing) | n/m | −16.62% (below 0%: shrinking) | 50.94% | (16.29%) | Compare |
| DCTH Delcath Systems, Inc. | $513.9M | 1,408× | — (loss-making) | +20.60% (above 0%: growing) | −12.50% (below 0%: shrinking) | −24.45% (below 0%: shrinking) | 89.75% | 8.22% | Compare |
| MASS 908 Devices Inc. | $491.5M | — (loss-making) | — (loss-making) | +23.31% (above 0%: growing) | n/m | +150.95% (above 0%: growing) | 51.90% | (79.69%) | Compare |
| SGHT Sight Sciences, Inc. | $484.8M | — (loss-making) | — (loss-making) | +19.55% (above 0%: growing) | n/m | +26.71% (above 0%: growing) | 91.39% | (16.62%) | |
| BWAY Brainsway Ltd. Sponsored ADR | $475.8M | 24.8× | — (loss-making) | +35.43% (above 0%: growing) | +40.00% (above 0%: growing) | −51.68% (below 0%: shrinking) | 74.62% | 13.98% | Compare |
| CERS Cerus Corporation | $455.5M | — (loss-making) | — (loss-making) | +5.28% (above 0%: growing) | n/m | −20.90% (below 0%: shrinking) | 55.91% | (2.94%) | Compare |
| NPCE NeuroPace, Inc. | $438.7M | — (loss-making) | — (loss-making) | +17.05% (above 0%: growing) | n/m | −78.70% (below 0%: shrinking) | 82.83% | (22.53%) | Compare |
| SENS Senseonics Holdings, Inc. | $435.2M | — (loss-making) | — (loss-making) | +117.82% (above 0%: growing) | n/m | −223.24% (below 0%: shrinking) | 59.10% | (248.48%) | Compare |
| Median of peers | $483.6M | 24.8× | — | +21.96% | +40.00% | −38.07% | 66.86% | (9.61%) |
Sight Sciences, Inc. (SGHT) key facts
- Concern: Sight Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $77.4 million, down 3.13% from fiscal 2024.
- Concern: Sight Sciences, Inc. reported a net loss of $38.4 million, or a loss of $0.74 per share, for fiscal 2025.
- Sight Sciences, Inc. (SGHT) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, SGHT traded at $8.28, a market capitalization of $484.8 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 5.4× sales.
- Return on equity was −50.7% and debt-to-equity 0.77.
- Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 0.83 (distress zone) for fiscal 2025.
Sight Sciences, Inc. (SGHT) Latest News
No news at this impact. Lower the threshold for more.